Inhibition of HUWE1 activity either by the pharmacologic compound BI8622 or by shRNA-mediated knockdown led to decreased growth and/or viability in MM cell lines as well as in a substantial fraction of primary MM samples, supporting a potential role of HUWE1 for malignant expansion. This evidence concerns the gene HUWE1 and Miyoshi myopathy.